+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
Healthy Volunteers
ID06968364

International Study to Evaluate the Safety and Accuracy of the Cervisense TPTL Device in Predicting Spontaneous Preterm Birth in Pregnant Women with Threatened Preterm Labor

Led by Ultrasound-Innovation Medtech, S.L. · Updated on 2025-05-13

457

Participants Needed

14

Research Sites

6 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and predictive ability of the Cervisense TPTL device in pregnant women showing symptoms of threatened preterm labor between 28 weeks and 36 weeks plus 6 days of gestation. The study aims to determine if the device can predict spontaneous preterm birth within 7 days and whether it is safe and reliable to use in hospital settings. This includes a Pilot Study with randomized groups and a Pivotal Study with a single group to confirm performance and safety. The trial involves two main study phases. In the Pilot Study, participants are randomly assigned to either receive the standard care or the Cervisense evaluation, which uses an intravaginal probe to measure cervical stiffness combined with clinical data by an algorithm. The Pivotal Study is a larger, single-arm phase where all participants receive the Cervisense evaluation. The main procedures include intravaginal measurements using the Cervisense Intravaginal Probe and comparison with transvaginal ultrasound cervicometry in the Pilot Study. Participants will be monitored from enrollment until delivery and followed for 14 days after the cervical assessment to track delivery outcomes and any adverse events. Researchers will assess the devices ability to predict preterm birth, monitor labor progression, record any trauma or pain related to device use, and collect feedback on technical reliability and operator satisfaction. Safety is closely observed with independent committees reviewing adverse events throughout the study period.

CONDITIONS

Brief Title

FB-CT2 Includes Two Prospective, Multi-centre Studies With a Medical Device in Hospital Settings: a Randomized, Dual-arm, Open-label Pilot Study in Spain, Followed by a Single-arm, Non-randomized, Open-label International Pivotal Study

Research Team

A

Alberto Maroto Ferrer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here